SCHEMBL23218889

SCHEMBL23218889

CCOC(=O)Cc1ccc(OC)cc1OCc1c2cc(Br)ccc2nn1C

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.39
HPGD P15428 4/20 0.39
KDM4E B2RXH2 3/20 0.39
GAA P10253 3/20 0.39
MAPT P10636 2/20 0.39
ELANE P08246 1/20 0.39
GLA P06280 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
CSF1R P07333 4/20 0.39
PDGFRB P09619 4/20 0.39
TDP1 Q9NUW8 1/20 0.39
NPC1 O15118 2/20 0.38
NCOA1 Q15788 1/20 0.38
NCOA3 Q9Y6Q9 1/20 0.38
MET P08581 2/20 0.38
JAK2 O60674 1/20 0.38
PAK4 O96013 1/20 0.38
NTRK1 P04629 1/20 0.38
LCK P06239 1/20 0.38
FYN P06241 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29853154 1.00 ALDH1A1 (0.39) ALDH1A1HPGDKDM4EGAAMAPT
SCHEMBL23218575 0.90 JAK2 (0.39) ALDH1A1HPGDKDM4EGAAMAPT
SCHEMBL29853030 0.90 JAK2 (0.39) ALDH1A1HPGDKDM4EGAAMAPT
SCHEMBL29853020 0.89 CSF1R (0.38) ALDH1A1HPGDKDM4EGAAMAPT
SCHEMBL23218860 0.89 CSF1R (0.38) ALDH1A1HPGDKDM4EGAAMAPT
SCHEMBL23218634 0.87 TBXAS1 (0.47) ALDH1A1HPGDKDM4EMAPTELANE
SCHEMBL29852508 0.87 TBXAS1 (0.47) ALDH1A1HPGDKDM4EMAPTELANE
SCHEMBL29122090 0.86 ALDH1A1 (0.36) ALDH1A1HPGDKDM4EGAAMAPT
SCHEMBL29122001 0.86 KMT2A (0.38) ALDH1A1HPGDKDM4EGAAMAPT
SCHEMBL23218159 0.84 ELANE (0.42) ALDH1A1HPGDKDM4EGAAMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12558341-B2 Oral complement factor D inhibitors BIOCRYST PHARMACEUTICALS, INC. (US) 2026-02-24 US disclosed
US-20250186391-A1 ORAL COMPLEMENT FACTOR D INHIBITORS WILMINGTON TRUST, NATIONAL ASSOCIATION 2025-06-12 US disclosed
CN-114502168-A Oral complement factor D inhibitors 拜奥克里斯特制药公司 2022-05-13 CN disclosed
WO-2021072198-A1 ORAL COMPLEMENT FACTOR D INHIBITORS BIOCRYST PHARMACEUTICALS, INC. (US) 2021-04-15 WO disclosed
WO-2021072198-A1 ORAL COMPLEMENT FACTOR D INHIBITORS BIOCRYST PHARMACEUTICALS, INC. (US) 2021-04-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12558341-B2 Oral complement factor D inhibitors CFD, CFH, CFB ALDH1A1 2667/4885HPGD 695/4885KDM4E 4172/4885
US-20250186391-A1 ORAL COMPLEMENT FACTOR D INHIBITORS CFD, CFH, CFB ALDH1A1 3142/4885HPGD 323/4885KDM4E 4491/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.